Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Regadenoson stress in patients with asthma and COPD: a breath of fresh air.

× No keyword cloud information.

7 in total

1. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group.

Authors: A Ranhosky; J Kempthorne-Rawson
Journal: Circulation Date: 1990-04 Impact factor: 29.690

2. Intravenous dipyridamole infusion causes severe bronchospasm in asthmatic patients.

Authors: K A Eagle; C A Boucher
Journal: Chest Date: 1989-02 Impact factor: 9.410

3. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry.

Authors: M D Cerqueira; M S Verani; M Schwaiger; J Heo; A S Iskandrian
Journal: J Am Coll Cardiol Date: 1994-02 Impact factor: 24.094

Review 4. Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease.

Authors: R Polosa; S Rorke; S T Holgate
Journal: Thorax Date: 2002-07 Impact factor: 9.139

5. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial.

Authors: Brian R Leaker; B O'Connor; Trevor T Hansel; Peter J Barnes; Lixen Meng; Vandana S Mathur; Hsiao D Lieu
Journal: J Nucl Cardiol Date: 2008-04-14 Impact factor: 5.952

6. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial).

Authors: Gregory S Thomas; Bruce R Tammelin; George L Schiffman; Rudy Marquez; Deborah L Rice; Douglas Milikien; Vandana Mathur
Journal: J Nucl Cardiol Date: 2008-04-14 Impact factor: 5.952

7. A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.

Authors: Bruce M Prenner; Stan Bukofzer; Sarah Behm; Kathleen Feaheny; Bruce E McNutt
Journal: J Nucl Cardiol Date: 2012-04-07 Impact factor: 5.952

7 in total

3 in total

1. Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.

Authors: Carlos Salgado Garcia; Carlos Salgado Garcia; Amelia Jimenez Heffernan; Amelia Jimenez Heffernan; Elena Sanchez de Mora; Carlos Ramos Font; Juana Lopez Martin; Francisco Rivera de los Santos; Ignacio Ynfante Milá
Journal: Eur J Nucl Med Mol Imaging Date: 2013-07-16 Impact factor: 9.236

Review 2. Regadenoson: a focused update.

Authors: Gopal Ghimire; Fadi G Hage; Jaekyeong Heo; Ami E Iskandrian
Journal: J Nucl Cardiol Date: 2013-04 Impact factor: 5.952

Review 3. Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.

Authors: Yasmeen Golzar; Rami Doukky
Journal: Int J Chron Obstruct Pulmon Dis Date: 2014-01-22

3 in total